Joshua Arbesman, MD

Assistant Professor
Department of Dermatology
School of Medicine
Assistant Professor
Department of Medicine
School of Medicine
Member
Molecular Oncology Program
Case Comprehensive Cancer Center

Dr. Joshua Arbesman joined the Dermatology Faculty of Case Western Reserve University (CWRU) School of Medicine in 2016. He attended the University at Buffalo, School of Medicine and Biomedical Sciences, Buffalo, New York. Dr. Arbesman completed an Internship in Internal Medicine at State University of New York (SUNY) at Buffalo’s affiliated hospitals. His Dermatology training was completed at University Hospitals Cleveland Medical Center in Cleveland, Ohio. Dr. Arbesman completed a Fellowship training program in Molecular and Investigative Dermatology, as a Post-Doctoral Fellow on T32 NIH Training Grant at CWRU/UHCMC.

Dr. Arbesman is currently a Case Comprehensive Cancer K12 Paul Calabresi Scholar, Clinical Oncology Research Career Development Program and he was recently awarded a Dermatology Foundation Medical Dermatology Career Development Award. He is a member of the American Academy of Dermatology and is a Board Certified Dermatologist.

Dr. Arbesman provides specialty care for patients with melanoma at University Hospitals Seidman Cancer Center. He also provides services across the full spectrum of general dermatology at the UH Chagrin Two facility.

Dr. Arbesman conducts basic science and clinical research in the areas of melanoma genetics and melanoma drug development.

Research Information

Research Interests

My research centers on the study of melanoma, specifically understanding the genetics of high risk melanoma families and the design of adjuvant therapies for melanoma management. My current work is involved in next-generation sequencing of high-risk melanoma families to determine novel melanoma susceptibility genes and the characterization of the overall genetics of familial melanoma. Additionally, I examine the repurposing of relatively safe, often previously clinically available, medications, to be used in the adjuvant therapy setting for melanoma patients. Preclinical work on this area is performed in a laboratory setting as preparation for future clinical trials.

External Appointments

Physician, Department of Dermatology
University Hospitals Cleveland Medical Center

Additional Information